INDIANAPOLIS, Sept. 21 (UPI) -- Eli Lilly and Amylin said Thursday their type 2 diabetes drug Byetta (exenatide) has been recommended for approval in Europe.
The company said the European Committee for Medicinal Products for Human Use has issued a positive recommendation of the drug as an adjunctive therapy to improve blood-sugar control in patients with type 2 diabetes who did not get results on metformin and/or sulfonylurea, two common diabetes therapies.
However, the European Commission must give its final approval, which the companies said they anticipate later this year.
The drug -- a first-in-class incretin mimetics treatment -- was approved in the United States in April 2005 for the same indication.
The companies said Byetta was tested in nearly 4,000 people in more than 20 countries.
